» Articles » PMID: 39335182

Vitamin D in Cancer Prevention and Treatment: A Review of Epidemiological, Preclinical, and Cellular Studies

Abstract

Inhibition of human carcinomas has previously been linked to vitamin D due to its effects on cancer cell proliferation, migration, angiogenesis, and apoptosis induction. The anticancer activity of vitamin D has been confirmed by several studies, which have shown that increased cancer incidence is associated with decreased vitamin D and that dietary supplementation of vitamin D slows down the growth of xenografted tumors in mice. Vitamin D inhibits the growth of cancer cells by the induction of apoptosis as well as by arresting the cells at the G0/G1 (or) G2/M phase of the cell cycle. Aim and Key Scientific Concepts of the Review: The purpose of this article is to thoroughly review the existing information and discuss and debate to conclude whether vitamin D could be used as an agent to prevent/treat cancers. The existing empirical data have demonstrated that vitamin D can also work in the absence of vitamin D receptors (VDRs), indicating the presence of multiple mechanisms of action for this sunshine vitamin. Polymorphism in the VDR is known to play a key role in tumor cell metastasis and drug resistance. Although there is evidence that vitamin D has both therapeutic and cancer-preventive properties, numerous uncertainties and concerns regarding its use in cancer treatment still exist. These include (a) increased calcium levels in individuals receiving therapeutic doses of vitamin D to suppress the growth of cancer cells; (b) hyperglycemia induction in certain vitamin D-treated study participants; (c) a dearth of evidence showing preventive or therapeutic benefits of cancer in clinical trials; (d) very weak support from proof-of-principle studies; and (e) the inability of vitamin D alone to treat advanced cancers. Addressing these concerns, more potent and less toxic vitamin D analogs have been created, and these are presently undergoing clinical trial evaluation. To provide key information regarding the functions of vitamin D and VDRs, this review provided details of significant advancements in the functional analysis of vitamin D and its analogs and VDR polymorphisms associated with cancers.

Citing Articles

A novel LC-MS/MS analysis of vitamin D metabolites in mice serum and hair: impact of diet and light exposure.

Hakeem M, Al-Menhali A, Elangovan S, Shah I Front Endocrinol (Lausanne). 2025; 16:1494393.

PMID: 39980854 PMC: 11841401. DOI: 10.3389/fendo.2025.1494393.


Comparative Analyses of the Safety Profiles of Vitamin D Receptor Agonists: A Pharmacovigilance Study Based on the EudraVigilance Database.

Gall Z, Kolcsar M Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770528 PMC: 11677518. DOI: 10.3390/ph17121686.

References
1.
Swami S, Krishnan A, Williams J, Aggarwal A, Albertelli M, Horst R . Vitamin D mitigates the adverse effects of obesity on breast cancer in mice. Endocr Relat Cancer. 2016; 23(4):251-64. PMC: 4889430. DOI: 10.1530/ERC-15-0557. View

2.
Suzuki T, Sano Y, Kinoshita S . Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice. Invest Ophthalmol Vis Sci. 2000; 41(1):154-8. View

3.
Woloszynska-Read A, Johnson C, Trump D . Vitamin D and cancer: clinical aspects. Best Pract Res Clin Endocrinol Metab. 2011; 25(4):605-15. PMC: 4729360. DOI: 10.1016/j.beem.2011.06.006. View

4.
Albert D, Scheef E, Wang S, Mehraein F, Darjatmoko S, Sorenson C . Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci. 2007; 48(5):2327-34. DOI: 10.1167/iovs.06-1210. View

5.
Keum N, Lee D, Greenwood D, Manson J, Giovannucci E . Vitamin D supplementation and total cancer incidence and mortality: a meta-analysis of randomized controlled trials. Ann Oncol. 2019; 30(5):733-743. PMC: 6821324. DOI: 10.1093/annonc/mdz059. View